
    
      Between 36 and 66 patients will be enrolled depending on the number of dose levels which can
      be completed. Patients will have histologically confirmed EFGR-expressing solid malignant
      tumours (colorectal cancer, head and neck cancer and NSCLC), which did not respond to
      standard therapy or for which no suitable therapy exists.
    
  